Preliminary phase Ia/Ib results of LY3321367 showed that the drug was well tolerated as a monotherapy and in combination with anti‐PD‐L1 LY3300054 (anti‐PD‐L1).[46] In this study, we found that LINC01232 derived from M2‐TAM exosomes promoted tumor immune escape through the E2F2/NBR1/MHC‐I signaling axis. Here, E2F2 is linked to neoplasm.